Literature DB >> 27896848

Composite endpoints and the distortion of risk-benefit analysis.

John B Warren1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27896848      PMCID： PMC5237691          DOI： 10.1111/bcp.13166

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Symmetrical analysis of risk-benefit.

Authors:  John B Warren; Simon Day; Peter Feldschreiber
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Proof That Lower Is Better--LDL Cholesterol and IMPROVE-IT.

Authors:  John A Jarcho; John F Keaney
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

3.  Composite endpoints and the distortion of risk-benefit analysis.

Authors:  John B Warren
Journal:  Br J Clin Pharmacol       Date:  2016-11-28       Impact factor: 4.335

4.  Cholesterol trials and mortality.

Authors:  John B Warren; Simon B Dimmitt; Hans G Stampfer
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

5.  Cumulative meta-analysis of therapeutic trials for myocardial infarction.

Authors:  J Lau; E M Antman; J Jimenez-Silva; B Kupelnick; F Mosteller; T C Chalmers
Journal:  N Engl J Med       Date:  1992-07-23       Impact factor: 91.245

6.  Long-term use of ticagrelor in patients with prior myocardial infarction.

Authors:  Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2015-03-14       Impact factor: 91.245
  6 in total
  3 in total

Review 1.  Translating the dose response into risk and benefit.

Authors:  John B Warren
Journal:  Br J Clin Pharmacol       Date:  2019-05-17       Impact factor: 4.335

2.  Composite endpoints and the distortion of risk-benefit analysis.

Authors:  John B Warren
Journal:  Br J Clin Pharmacol       Date:  2016-11-28       Impact factor: 4.335

Review 3.  The pharmacodynamic and clinical trial evidence for statin dose.

Authors:  Simon B Dimmitt; Hans G Stampfer; John B Warren
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.